Overview

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c >10% Phase: Phase 3
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide